1360431-86-2 Usage
Uses
Used in Pharmaceutical Industry:
C29H26ClFN4O5S is used as an intermediate compound in the metabolism of lapatinib, a dual kinase inhibitor, for the treatment of various types of cancer. Its presence in the human body helps in the breakdown and utilization of lapatinib, which targets and inhibits the activity of specific enzymes involved in cancer cell growth and proliferation.
Used in Cancer Treatment:
C29H26ClFN4O5S is used as a therapeutic agent in the treatment of cancer, particularly in combination with lapatinib. It aids in the inhibition of cancer cell growth by targeting and blocking the activity of specific kinases, which are enzymes that play a crucial role in cell signaling and regulation. This dual inhibition approach helps in controlling the progression of cancer and improving the overall treatment outcomes for patients.
Used in Research and Development:
C29H26ClFN4O5S is also used in the research and development of new drugs and therapies for cancer treatment. Its unique molecular structure and properties make it a valuable compound for studying the mechanisms of action, drug interactions, and potential side effects of lapatinib and other similar drugs. This knowledge can be applied to the development of more effective and safer cancer treatments in the future.
Check Digit Verification of cas no
The CAS Registry Mumber 1360431-86-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,0,4,3 and 1 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1360431-86:
(9*1)+(8*3)+(7*6)+(6*0)+(5*4)+(4*3)+(3*1)+(2*8)+(1*6)=132
132 % 10 = 2
So 1360431-86-2 is a valid CAS Registry Number.
1360431-86-2Relevant academic research and scientific papers
N-SUBSTITUTED 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE
-
Paragraph 0111, (2016/03/22)
The present invention provides kinase inhibitor analogs with improved properties, such as improved efficacy, pharmacokinetics, safety, and specificity. In some embodiments, the present invention provides lapatinib analogs that provide therapeutic benefits
